Chardan Acts as Lead Left Bookrunner in Femasys' $34.45 Million IPO
On June 21, 2021, Chardan announced its role as the lead left bookrunner for the $34.45 million IPO of Femasys, Inc. (NASDAQ: FEMY), a biomedical company dedicated to women's healthcare. The funds raised will support Femasys’ clinical trials for its FemBloc and FemaSeed systems, along with product development and hiring efforts. Chardan has prioritized investing in healthcare companies addressing significant unmet needs, reflecting a commitment to ESG principles.
- Successful closing of a $34.45 million IPO for Femasys.
- Proceeds to fund clinical trials, product development, and staffing.
- None.
NEW YORK, June 21, 2021 /PRNewswire/ -- Chardan, a global investment bank, today announced that it acted as lead left bookrunner in the successful closing of the
"We are delighted to work with the outstanding team at Femasys in support of their commitment to women's healthcare," said Matthew Mrozinski, a partner in the investment banking group at Chardan. "Chardan's goal as a bank is to identify and support companies that address areas of significant unmet need. Femasys' mission of transforming women's healthcare is a substantial market opportunity."
This transaction further solidifies Chardan's dedication to ESG and healthcare companies with novel and differentiated platforms. Since 2020, Chardan has acted as book runner or lead placement agent in 32 transactions including for healthcare companies: 4D Pharma plc (PIPE), Forge Biologics (Private offering) Forte Biosciences (FO), GenSight Biologics (PIPE), Immunome (IPO), Immunovant (FO), MeiraGTx (FO), NeuBase Therapeutics (FO), and Renovacor (announced PIPE).
Femasys is a woman-led company founded by Kathy Lee-Sepsick, President, CEO and Founder. Femasys will use the proceeds of their IPO to fund the completion of enrollment in the stage 2 clinical trial and commencement of the stage 3 clinical trial for the FemBloc system and for the initiation and completion of the pivotal trial for the FemaSeed system. The proceeds will also be used to fund product development and research and development activities, to hire additional personnel, and for working capital and general corporate purposes.
About Chardan
Chardan is an independent global investment bank specializing in healthcare, SPACs and emerging growth companies. Our range of services include capital raising, merger and acquisition advisory, strategic advisory, equity research, corporate access, and institutional trading. Headquartered in New York City, Chardan is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: FINRA, SIPC, NASDAQ and the NYSE Arca, Inc.
Media Inquiries:
Emily Levine, Chardan
elevine@chardan.com
(646) 465-9018
Margaret Gaenzle, Prosek Partners
mgaenzle@prosek.com
(804) 714-8848
View original content:http://www.prnewswire.com/news-releases/chardan-acts-as-lead-left-bookrunner-in-femasys-34-45-million-ipo-301316312.html
SOURCE Chardan
FAQ
What is the significance of Femasys' recent IPO?
Who acted as the bookrunner for Femasys' IPO?
How will Femasys utilize the funds from its IPO?
What is Femasys' focus in healthcare?
When was Femasys' IPO announced?
